tiprankstipranks
Advertisement
Advertisement

CABA Stock Latest News

Douglas Tsao Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target on Rese-cel’s Emerging Commercial Profile and Conditioning-Free Edge
RatingsDouglas Tsao Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target on Rese-cel’s Emerging Commercial Profile and Conditioning-Free Edge
16d ago
CABA
Analyst Reiterates Buy on Cabaletta Bio Citing Strong Cash Runway and Promising Early Rese-cel Data in Autoimmune Diseases
PremiumRatings
Analyst Reiterates Buy on Cabaletta Bio Citing Strong Cash Runway and Promising Early Rese-cel Data in Autoimmune Diseases
17d ago
CABA
Analyst Reiterates Buy on Cabaletta Bio, Citing Strong Non-Preconditioned PV Data, Scalable Manufacturing, and Multiple Upcoming Catalysts
PremiumRatings
Analyst Reiterates Buy on Cabaletta Bio, Citing Strong Non-Preconditioned PV Data, Scalable Manufacturing, and Multiple Upcoming Catalysts
17d ago
CABA
Cabaletta Bio presents new clinical data for rese-cel
PremiumThe Fly
Cabaletta Bio presents new clinical data for rese-cel
17d ago
CABA
Cabaletta Bio reports Q1 EPS (39c), consensus (39c)
PremiumThe Fly
Cabaletta Bio reports Q1 EPS (39c), consensus (39c)
17d ago
CABA
Cabaletta Bio Reports Encouraging RESET-PV Trial Data
PremiumCompany AnnouncementsCabaletta Bio Reports Encouraging RESET-PV Trial Data
17d ago
8K
CABA
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed
Premium
Ratings
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed
27d ago
CABA
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
Premium
The Fly
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
27d ago
CABA
Cabaletta Bio Announces $150 Million Equity Offering
PremiumCompany Announcements
Cabaletta Bio Announces $150 Million Equity Offering
27d ago
8K
CABA
Cabaletta Bio reports promising RESET-PV and RESET-SLE data
PremiumCompany Announcements
Cabaletta Bio reports promising RESET-PV and RESET-SLE data
27d ago
8K
CABA
Cabaletta Bio: Buy Rating Reiterated as Rese-cel Data and Cellares Partnership Support Unchanged $16 Price Target
PremiumRatings
Cabaletta Bio: Buy Rating Reiterated as Rese-cel Data and Cellares Partnership Support Unchanged $16 Price Target
1M ago
CABA
Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel
PremiumThe Fly
Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel
1M ago
CABA
Cabaletta Bio, Cellares enter 10-year commercial agreement
PremiumThe FlyCabaletta Bio, Cellares enter 10-year commercial agreement
1M ago
CABA
Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential
Premium
Ratings
Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential
1M ago
CABA
Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans
Premium
Company Announcements
Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans
1M ago
8K
CABA
Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle
PremiumThe Fly
Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle
2M ago
CABA
Morgan Stanley and Jefferies Analysts Forecast Over 350% Upside Potential for Cabaletta Bio Stock
PremiumMarket News
Morgan Stanley and Jefferies Analysts Forecast Over 350% Upside Potential for Cabaletta Bio Stock
2M ago
MS
JEF
Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley
PremiumThe Fly
Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley
2M ago
CABA
Cabaletta Bio price target raised to $16 from $15 at Guggenheim
PremiumThe Fly
Cabaletta Bio price target raised to $16 from $15 at Guggenheim
2M ago
CABA
Midday Fly By: Musk to start Terafab project, Elliott takes stake in Synopsys
PremiumThe FlyMidday Fly By: Musk to start Terafab project, Elliott takes stake in Synopsys
2M ago
MP
DBX
Cabaletta Bio Updates Rese-cel Programs and Financial Outlook
Premium
Company Announcements
Cabaletta Bio Updates Rese-cel Programs and Financial Outlook
2M ago
8K
CABA
Cabaletta Bio reports Q4 EPS (40c), consensus (47c)
Premium
The Fly
Cabaletta Bio reports Q4 EPS (40c), consensus (47c)
2M ago
CABA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >